Citations

Clear

1446 citation(s) found for "Howard, F".

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
Tang, Hoi Ki Karen, Fung, Chi Yeung, Kumar, Shaji , Siu, Lisa L. P. , Ip, Ho Wan Alvin, Yip, Sze Fai, Lau, Ka Ngai Harry, Lau, Chi Kuen, Leung, Kwan Hung, Kho, B C S, Wong, Howard, Ngai, Cheong , Hwang, Yu Yan, Sim, Joycelyn, Kumar, Shaji K , Chim, Chor Sang , Morgan, Gareth J. , Lee, Harold , Wong, Howard, Hwang, Yu‐Yan , Kwong, Yok‐Lam , Chim, Chor Sang

Mayo Clinic

Therapeutic Advances in Hematology | April 18, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20406207221082043 | PMID 35465644 Get It

Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. Methods: To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescence in situ hybridization (FISH) performed on CD138-sorted bone marrow aspirate, and plasma cells were analysed using DNA probes specific for the following chromosomal aberrations: del(13q14), del(17p), t(14;16), t(4;14), and +1q. Presence of +1q was defined as the presence of at least three copies of 1q21 at the cut off level of 20% of bone marrow plasma cells. Results: +1q identified in 167 (66.8%) and associated with t(4;14) and high lactate dehydrogenase (LDH). +1q was not associated with response rate but shorter event-free survival (EFS) (median EFS 35 vs 55 months, p = 0.05) and overall survival (OS) (median OS 74 vs 168 months, p = 0.00025). Copy number and clone size did not impact survival. Multivariate analysis showed +1q was an independent adverse factor for OS together with International Staging System (ISS)3, high LDH, del(17p) and t(4;14). When a risk score of 1 was assigned to each independent adverse factor, OS was shortened incrementally by a risk score from 0 to 4. Post-relapse/progression survival was inferior in those with +1q (median 60 vs 118 months, p = 0.000316). Autologous stem cell transplantation (ASCT) improved OS for those with +1q (median OS 96 vs 49 months, p = 0.000069). Conclusion: +1q is an adverse factor for OS in MM uniformly treated with bortezomib-based induction but was partially mitigated by ASCT. A risk scoring system comprising +1q, LDH, high-risk FISH, and ISS is a potential tool for risk stratification in MM.
Efficacy and Safety of Twice-Daily versus Three-Times Daily Saquinavir Soft Gelatin Capsules as Part of Triple Combination Therapy for HIV-1 Infection
Wheat, L. Joseph , Farthing, Charles, Cohen, Calvin, Pierone, Gerald , Lalezari, Jay , Pilson, Robert S, Siemon-Hryczyk, Peggy, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Baxter, John, Beer, Victor L., Bellos, Nicholas, Bissett, Jack, Braun, James, Brosgart, Carol, Burnside, Alfred F., Cervia, Joe, Cheeseman, Sarah H., Cimoch, Paul J., Cohen, Calvin, DeJesus, Edwin, Diaz, Leslie L, Dieterich, Douglas T. , Dobkin, Jay F., Dretler, Robin, El-Sadr, Waafa, Eng, Robert H.K., Feleke, Getachew, Fessel, Jeffrey , Fish, Douglas N. , Galpin, Jeffrey E., Gathe, Joseph, Gilson, Ian, Gold, Marla, Goodgame, Jeffrey, Greenberg, Richard N. , Greiger, Paola, Grossman, Howard, Grossman, Ron, Hanna, Barbara, Hathaway, Bruce, Hoffman-Terry, Margaret, Jacobson, Susan , Jemsek, Joseph G., Jordan, Wilbert, Kaplan, Mark, Kostman, Jay R., Landesman, Sheldon H., Lindquist, Craig, Madhava, Valsa, Marsh, Bryan J., Martin, Dean, Mathur‐Wagh, Usha, McMeeking, Alexander, Miao, Peter, Mogyoros, Miguel, Mustafa, Mahmoud M., Nadler, Jeffrey P., Norris, Dorece, Onbirbak, Brian, Parker, Richard H, Pearce, Daniel, Pierone, Gerald, Poblete, Ronald, Poretz, Donald M., Reyelt, M Christine, Rivera-Vazquez, Carlos, Salvato, Patricia, Sands, Michael, Schwartz, Robert A., Sension, Michael, Skowron, Gail, Slater, Leonard N., Stavola, Joseph, Steinhart, Corklin, Temesgen, Zelalem , Thompson, Melanie , Timpone, Joseph, Vollmer, Kelly, Wada, Suzanne, Wheat, L Joseph, Yangco, Bienvenido G., Carey, Peter, Jablonowski, H, Theisen, Albert, Ocana, Inma, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Burman, William J. , Cohen, Calvin, Feinberg, Judith , Goodrich, James , Jacobson, Susan, Kaplan, Mark, Lalezari, Jacob , MacArthur, Rodger D. , Murphy, Robert L. , Mustafa, Mahmoud, Pierone, Gerald, Reyelt, M. Christine, Smith, David C. , Valentine, Fred T. , Ward, Douglas, Wheat, L Joseph, Carey, Peter, Lazzarin, Adriano , Ocana, Inma

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 7 | Issue: 3 | Pages: 199-209

10.1177/135965350200700310 Get It

Objective The objective of this study was to determine whether a triple therapy regimen incorporating twice-daily saquinavir is as effective as a three-times daily regimen. Methods This was an open-label, Phase III, multicentre, 48-week study involving 837 HIV-1-infected patients randomised to one of the following: saquinavir soft gel capsule (SGC) 1200 mg three-times daily, plus two nucleoside reverse transcriptase inhibitors (NRTIs) (arm A); saquinavir SGC 1600 mg twice-daily, plus two NRTIs (arm B); saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily, plus a single NRTI (arm C). The primary outcome measure was the virological response in arm A versus B and in arm A versus C with respect to the percentage of patients whose plasma HIV-1 RNA levels fell below the level of quantification for the Amplicor assay (<400 copies/ml) at weeks 24 and 48. Results At 48 weeks, the percentage of patients with plasma HIV-1 RNA levels <400 copies/ml was 47.1% (arm A), 45.3% (arm B) and 42.7% (arm C) in the intention-to-treat analysis. The treatment difference between arm B–arm A was -1.8% (95% confidence intervals -10.1, 6.5) and for arm C–arm A was -4.5% (95% confidence intervals -12.7, 3.7) in the intention-to-treat analysis. These differences fell within the maximum allowable difference (±12%) for arm B compared with arm A. At week 24, the percentage of patients with HIV-1 RNA levels <400 copies/ml was 59.6% (arm A), 57.6% (arm B) and 51.3% (arm C). Conclusions A twice-daily triple therapy regimen incorporating saquinavir SGC plus two NRTIs was of equivalent efficacy to the three-times daily regimen studied. All regimens were generally well tolerated.
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
Klonoff, David C. , Wang, Jing , Rodbard, David , Kohn, Michael A. , Li, Chengdong , Liepmann, Dorian , Kerr, David , Ahn, David , Peters, Anne L. , Umpierrez, Guillermo E. , Xu, Nicole Y. , Nguyen, Kevin T. , Simonson, Gregg D. , Agus, Michael S. D. , Armaiz-Peña, Gustavo , Basu, Ananda , Battelino, Tadej , Yeshiwas, Sewagegn , Bequette, B. Wayne , Blevins, Thomas , Breton, Marc D. , Castle, Jessica R. , Close, Kelly L. , Drincic, Angela, Dungan, Kathleen , Ejskjær, Niels , Espinoza, Juan , Fleming, G. Alexander , Forlenza, Gregory P. , Freckmann, Guido , Galindo, Rodolfo J. , Gómez, Ana María , Gutow, Hanna A. , Hovorka, Roman , Ji, Linong , Joubert, Michaël , Koliwad, Suneil K. , Lal, Rayhan , Lansang, M. Cecilia , Lee, Wei-An , Leelarathna, Lalantha , Lind, Marcus , Mahoney, Katherine , Mankovsky, Boris , Masharani, Umesh , Mathioudakis, Nestoras , Mayorov, Alexander Yur'evich , Messler, Jordan , Mohan, Viswanathan , Nichols, James H. , O’Neal, David N. , Pasquel, Francisco J. , Philis‐Tsimikas, Athena , Phillip, Moshe , Rayman, Gerry , Russell, Steven J. , Spanakis, Elias K. , Waki, Kayo , Wallia, Amisha , Weinberg, Melissa E. , Wolpert, Howard , Zilbermint, Mihail , Kovatchev, Boris , Seley, Jane Jeffrie , Xu, Nicole Y , Nguyen, Kevin T , Simonson, Gregg , Agus, Michael S D , Al-Sofiani, Mohammed E , Armaiz-Pena, Gustavo , Bailey, Timothy S , Basu, Ananda , Battelino, Tadej , Bekele, Sewagegn Yeshiwas , Benhamou, Pierre-Yves , Bequette, B Wayne , Blevins, Thomas , Breton, Marc D , Castle, Jessica R , Chase, James Geoffrey , Chen, Kong , Choudhary, Pratik , Clements, Mark A , Close, Kelly L , Cook, Curtiss B , Doyle, Francis J , Drincic, Angela , Dungan, Kathleen M , Edelman, Steven V , Ejskjaer, Niels , Espinoza, Juan , Fleming, G Alexander , Forlenza, Gregory P , Freckmann, Guido , Galindo, Rodolfo J , Gomez, Ana Maria , Gutow, Hanna A , Heinemann, Lutz , Hirsch, Irl B , Hoang, Thanh D , Hovorka, Roman , Jendle, Johan H , Ji, Linong , Joshi, Shashank R , Joubert, Michael , Koliwad, Suneil K , Lal, Rayhan A , Lansang, M Cecilia , Lee, Wei-An Andy , Leelarathna, Lalantha , Leiter, Lawrence A , Lind, Marcus , Litchman, Michelle L , Mader, Julia K , Mahoney, Katherine M , Mankovsky, Boris , Masharani, Umesh , Mathioudakis, Nestoras N , Mayorov, Alexander , Messler, Jordan , Miller, Joshua D , Mohan, Viswanathan , Nichols, James H , Nørgaard, Kirsten , O'Neal, David N , Pasquel, Francisco J , Philis-Tsimikas, Athena , Pieber, Thomas , Phillip, Moshe , Polonsky, William H , Pop-Busui, Rodica , Rayman, Gerry , Rhee, Eun-Jung , Russell, Steven J , Shah, Viral N , Sherr, Jennifer L , Sode, Koji , Spanakis, Elias K , Wake, Deborah J , Waki, Kayo , Wallia, Amisha , Weinberg, Melissa E , Wolpert, Howard , Wright, Eugene E , Zilbermint, Mihail , Kovatchev, Boris , Kohn, Michael , Umpierrez, Guillermo E. , Peters, Anne L , Ahn, David T , Liepmann, Dorian , Bailey, Timothy S. , Chen, Kong Y. , Choudhary, Pratik , Cook, Curtiss B. , Danne, Thomas , Doyle, Francis J. , Heinemann, Lutz , Hirsch, Irl B. , Leiter, Lawrence A. , Mader, Julia K. , Pop‐Busui, Rodica , Shah, Viral N. , Sode, Koji , Wright, Eugene E.

Mayo Clinic

Journal of Diabetes Science and Technology | March 29, 2022 | Volume: 17 | Issue: 5 | Pages: 1226-1242

10.1177/19322968221085273 | PMID 35348391 Get It

Background: A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data. Methods: We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low–glucose and low-glucose hypoglycemia; very high–glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation. Results: The analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals. Conclusion: The GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.
Abstract TP338: Outcomes After Carotid Endarterectomy Among Dual-eligible Medicare-Medicaid Beneficiaries, 2003-2010
Lichtman, Judith H. , Leifheit-Limson, Erica C, Wang, Yun , Brott, Thomas G. , Meschia, James F. , Howard, George , Howard, Virginia J.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 47 | Issue: suppl_1 | Pages: No page available

10.1161/str.47.suppl_1.tp338 Get It

Background: Over 9 million dual-eligible beneficiaries rely on both Medicare and Medicaid to obtain critical medical services. Medicaid serves as a safety net for low-income Medicare beneficiaries with limited assets; however, it is unknown whether dual-eligible patients have comparable outcomes for procedures to non-dual-eligible Medicare beneficiaries. We compared outcomes by dual-eligible status for patients undergoing carotid endarterectomy (CEA). Methods: We identified Medicare fee-for-service beneficiaries aged ≥65y who underwent CEA (ICD-9 38.12) from 2003-2010. Beneficiaries with ≥1m of Medicaid coverage were considered dual eligible. We fit mixed models with a random intercept for state and adjustment for demographics, comorbidities, and symptomatic status to assess the relationship between dual-eligible status and outcomes. Results: A total of 35,832 dual-eligible and 470,134 non-dual-eligible beneficiaries were hospitalized for CEA during the study period. The percentage of dual-eligible CEA patients decreased from 7.9% in 2003 to 6.7% in 2010. Dual eligibles were more likely to be younger, female, of nonwhite race, and living with comorbid conditions (e.g., heart failure, renal failure, diabetes) and symptomatic carotid disease. Dual eligibles had higher 30d composite outcomes including stroke (Table), but the associations with 1y stroke became nonsignificant from 2003-2010. Dual-eligible status was associated with higher 30d and 1y mortality after CEA throughout the study period. Conclusions: Dual-eligible Medicare-Medicaid beneficiaries had worse short-term stroke and mortality outcomes than other beneficiaries, even after adjustment for comorbidities. Our results indicate a need to understand factors contributing to poorer outcomes. Challenges include the split accountability between the two programs and the diverse sociodemographics, clinical characteristics, and generally poorer health of the patients.
Abstract W MP108: Accuracy of Diagnoses in Contemporary Medicare Data: REGARDS Study Linked With Medicare Claims
Ramachandran, Rekha , Hardy, N. Chantelle , Rhodes, J. , Safford, Monika M. , Jalbert, Jessica J. , Brott, Thomas G. , Setoguchi, Soko , Kumamaru, Hiraku , Judd, Suzanne E. , Curtis, Jeffrey R. , Kissela, Brett , Howard, George

Mayo Clinic

Stroke | March 20, 2022 | Volume: 45 | Issue: suppl_1 | Pages: No page available

10.1161/str.45.suppl_1.wmp108 Get It

Background: Administrative data such as Medicare data are commonly used for health services research and comparative effectiveness studies. These databases are readily available and a good source of long-term data on healthcare utilization and health outcomes in real-world settings. Outcomes are captured using diagnostic codes, but the evidence on the validity of these codes is scarce in contemporary Medicare data. Methods: We linked the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study data using SSN, date of birth and sex to 2003-2009 Medicare claims. In addition to the events captured by REGARDS phone interviews, medical charts were pursued for Medicare-identified strokes not previously identified in REGRADS. Events were adjudicated by stroke specialists using the retrieved medical charts. Using all the adjudicated strokes as gold standard, we calculated the sensitivity, specificity, PPV and NPV of inpatient stroke algorithms with ICD-9-CM codes [430, 431, 433.x1, 434.x1, 436] in the primary discharge diagnosis. Results: We successfully linked 15,089 REGARDS participants with mean age of 69.3, 52% female and 37% Black. We adjudicated 457 strokes, of which 48 were identified by claims only and not by interviews. The tested algorithms had high specificity (99.8-100%), PPV (88.6-90.5%) and NPV (98.9-99.9%), but low sensitivity (58.6-67.4%) (Table). Conclusions: High specificity and PPV of our algorithms to identify strokes in contemporary Medicare populations support their use in etiological and comparative effectiveness studies. While our inpatient Medicare algorithms identified 12% extra cases of strokes, their usefulness for estimating stroke incidence or related healthcare utilizations is limited by their low sensitivity. Linking cohorts to Medicare data is feasible and should be considered to increase the completeness of follow-up. Further studies are needed to evaluate more sensitive Medicare algorithms.
Abstract WP160: A Post-Hoc Assessment of Current Hormone Therapy on Revascularization Risk in Women: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)
Mackey, Ariane , Lutsep, Helmi L. , Milot, Geneviève , Voeks, Jenifer H. , Hughes, Susan , Tom, MeeLee , Longbottom, Mary, Sheffet, Alice J., Brott, Thomas G. , Howard, Virginia J.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.awp160 Get It

Background: Hormone replacement therapy (HRT) was among factors considered in a post-hoc assessment of the risk of revascularization by carotid artery stenting (CAS) or carotid endarterectomy (CEA) in women enrolled in CREST. Methods: Of the 872 women in CREST, 775 (89%) were post-menopausal and current HRT status was known in 739 (95%). The study composite outcome was defined as any stroke, myocardial infarction, or death during the periprocedural period, plus ipsilateral stroke over a 4-year follow-up period. Treatment groups were combined and differences in the composite outcome were assessed by current HRT at baseline. Results: There were 77/739 (10%) current HRT users. HRT users were more likely to be symptomatic at baseline than non-users (65% vs. 52%; p = 0.027), and were less likely to be diabetic (19% vs. 32%; p = 0.024). However, they were similar in most other factors including age, race, hypertension, dyslipidemia, smoking status, and length of follow-up (p > 0.10). There were no (0) periprocedural events among the 77 HRT users while there were 43 (6.5%) events among the 662 non-users (p = 0.017). Among those event-free at the end of the periprocedural period, there was little evidence of an impact of baseline HRT on the risk of ipsilateral stroke with 2 (2.6%) post-procedural events among 77 HRT users and 12 (1.9%) among 619 non-users. Conclusion: We found that women on current HRT have lower periprocedural risk associated with CAS or CEA than non-users, but little difference in risk after the procedural period. The mechanism for this unexpected finding is elusive. We urge caution in the interpretation of this post-hoc observation and encourage replication or refutation by other revascularization studies with similar data.
Abstract TP124: Mediators of the Age Effect among Patients Treated with Carotid Artery Stenting: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)
Voeks, Jenifer H. , Farb, Richard , Heck, Donald , Roubin, Gary S., Moore, Wesley S. , Logan, W. R., Longbottom, Mary, Brott, Thomas G. , Logan, William, Howard, George

Mayo Clinic

Stroke | March 20, 2022 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.atp124 Get It

Background An increased risk of periprocedural stroke and death has been reported for older patients treated with carotid stenting (CAS). Selection of patients for CAS could be improved if patient or artery characteristics responsible for this higher risk could be identified. Methods The 1123 CREST patients randomized to CAS who received CAS within 30-days were analyzed. From the CREST sites, risk factors for atherosclerosis (hypertension, diabetes, and dyslipidemia) and arterial characteristics by angiography (lesion length, eccentric lesions, ulcerated lesions, and percent stenosis) were assessed. From the CREST core labs, potential mediators of the age effect included peak systolic velocity (ultrasound core, available on 853 patients) and arterial characteristics (angiographic core, available on 1042 patients, narrow/no ulcer or wide mouth, lesion location, and distal tortuosity). Mediation analysis assessed impact of adjustment for these factors on the magnitude of the estimated increased risk for CAS at older ages. Results After adjustment for sex and symptomatic status, there was a 1.72-times (95% CI: 1.26 - 2.37) increased risk of periprocedural stroke and death associated with each decade of patient age. Adjustment for lesion length as assessed in the clinical center significantly attenuated this increased risk at older ages to 1.66 (95% CI: 1.20 - 2.29, p = 0.039), an 8.3% attenuation. No other factor showed evidence as a contributor to the periprocedural increased risk of stroke and death in older patients (p > 0.10). Conclusion These data suggest that a longer carotid artery lesion length is a significant contributor to the increased risk of CAS in the elderly. However, attenuation of the age effect was modest, less than a 10% change in the hazard ratios. Other potential mediators such as tortuosity and atherosclerosis of the aortic arch and great vessels were not assessed. Non-anatomic factors that are more common with advancing age such as cerebral white matter disease and subclinical dementia were also not assessed and may play a role in how elderly patients respond to ischemic insults.
Abstract 69: Can Patient or Arterial Characteristics Guide the Choice between Carotid Angioplasty and Carotid Endarterectomy? The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)
Moore, Wesley S. , Roubin, Gary S., Altafullah, Irfan, Ansel, Gary M. , Voeks, Jenifer H. , Lal, Brajesh K. , Brott, Thomas G. , Rosenfield, Kenneth , Meschia, James F. , Howard, George

Mayo Clinic

Stroke | March 20, 2022 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.a69 Get It

Background: We have previously reported that carotid artery stenting (CAS) carries a higher stroke risk than carotid endarterectomy (CEA) in patients over the age of 70. The question arises if advanced age is a surrogate for other factors? If so, can those factors be separately identified such that advanced chronological age alone would not be considered a contra-indication for CAS? Here we consider whether the CAS/CEA choice could be guided by other factors known in the clinical center at the time of patient evaluation, independent of age, in order to provide optimal 4-year outcomes. Methods: Demographic factors (age, sex and race), symptomatic status, patient risk factors (hypertension, diabetes, dyslipidemia, smoking), and arterial characteristics (percent stenosis) were available on 2,502 patients. Additional detailed arterial characteristics (ulcerated plaque, distal tortuosity, sequential lesions, circumferential calcification) were available on 1141 CAS and 438 CEA patients. Potential differential treatment efficacy was assessed by the addition of factor-by-treatment interaction terms to a proportional hazard model containing established predictors of outcome (treatment, symptomatic status, sex, age and age-by-treatment interaction). Results: No other factor was found to mitigate advanced age with evidence of additional treatment effect modification of 4-year outcome (p > 0.10). Discussion: Beyond the previously described differential treatment efficacy by age, there were no other patient or arterial characteristic detected to identify patient subgroups that would differentially benefit from the choice of CAS versus CEA. Our inability to identify factors to guide treatment choices could be due to the low number of stroke and death events, incomplete information regarding arterial characteristics in the CEA population, or the potential exclusion of “high risk” groups (such as those with severe arterial tortuosity) from the study.
Abstract 1: Did Carotid Stenting and Endarterectomy Outcomes Change Over Time in the Carotid Revascularization Endarterectomy versus Stenting Trial?
Roubin, Gary S., Hopkins, L. Nelson , Moore, Wesley S. , Gray, William A. , Katzen, Barry T. , Chakhtoura, Elie, Morrish, William, Ferguson, R. , Shawl, Fayaz A., Harrigan, Mark R. , Voeks, Jenifer H. , Lal, Brajesh K. , Brott, Thomas G. , Howard, George , Rosenfield, Kenneth , Hye, Robert J. , Meschia, James F.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a1 Get It

Background The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) enrolled 2502 patients between December of 2000 and mid-July of 2008. We analyzed temporal changes in outcomes for both CEA and CAS over the course of this study. Methods Enrollment was divided into 3 consecutive epochs (5 years, 14 months, and 16 months), each with approximately 834 patients ( Table ). Rates for the primary outcome of death, stroke, and myocardial infarction (DSMI) and for death and stroke (DS) during the periprocedural period were calculated. Poisson regression was used to adjust rates for age, sex, dyslipidemia, and symptomatic status, all of which were found to influence outcomes. Results For CAS, there was a 26% decline in DSMI (6.2% → 4.6%) and a 35% decline in DS (5.5% → 3.6%). For both composite endpoints in CEA there was no consistent pattern ( Table ). As CREST progressed, it enrolled younger patients, more men, patients more likely to be dyslipidemic and enrolled more asymptomatic patients (all p < 0.05). Adjustment for these changes mediated the improvement in event rates for the CAS patients, and had no consistent effect on CEA event rates ( Table ). Conclusion Periprocedural safety for CAS improved over time in CREST. Changes were inconsistent for CEA. Improvements for CAS in part appear to reflect changes in patient selection related to age, sex, and risk factors, as adjustment for those variables attenuated the decline in rates. Linking rates to operator experience was not feasible because of the large number of new interventionalists and surgeons entering CREST over time.
Lessons Learned during COVID-19: Safety of Vascularized Omental Lymphatic Transfer in the Outpatient Setting
Kandi, Lyndsay A., Rebecca, Alanna M., Howard, Michael A., Teven, Chad M., Kandi, Lyndsay A. , Rebecca, Alanna M., Howard, Michael A., Teven, Chad M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | March 18, 2022 | Volume: 10 | Issue: 3 | Pages: e4231

10.1097/gox.0000000000004231 | PMID 35317461 Get It